Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study of Intravenous Daclizumab in Patients With Moderate-to-severe Ulcerative Colitis

NCT00073047 is registered in ClinicalTrials.gov with Facet Biotech as lead sponsor.

NCT NCT00073047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00073047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study of Intravenous Daclizumab in Patients With Moderate-to-severe Ulcerative Colitis
Lead sponsor
Facet Biotech
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
July 31, 2006
Enrollment
150
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal disease, inflammatory bowel disease, ulcerative colitis